# EDGAR Filing Document

**Accession Number:** 0001832928
**File Stem:** 0001832928-25-000026
**Filing Date:** 2025-9
**Character Count:** 7337
**Document Hash:** 922880e2be24850539ec6eef6946c337
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001832928-25-000026.hdr.sgml**: 20250918

**ACCESSION NUMBER**: 0001832928-25-000026

**CONFORMED SUBMISSION TYPE**: SC TO-I/A

**PUBLIC DOCUMENT COUNT**: 12

**FILED AS OF DATE**: 20250918

**DATE AS OF CHANGE**: 20250918

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cresco Labs Inc.
- **CENTRAL INDEX KEY:** 0001832928
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981505364
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-I/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92428
- **FILM NUMBER:** 251324229

**BUSINESS ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
- **BUSINESS PHONE:** (312) 929-0993

**MAIL ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cresco Labs Inc.
- **CENTRAL INDEX KEY:** 0001832928
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 981505364
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC TO-I/A

**BUSINESS ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661
- **BUSINESS PHONE:** (312) 929-0993

**MAIL ADDRESS:**
- **STREET 1:** 600 W. FULTON STREET, SUITE 800
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60661

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION <br>Washington, D.C. 20549**

**SCHEDULE TO/A**

**(Amendment No. 1)<br>TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF<br>THE SECURITIES EXCHANGE ACT OF 1934**

**Cresco Labs Inc.**

**(Name of Subject Company (Issuer))**

**Cresco Labs Inc., as Issuer and Offeror**

**(Name of Filing Persons (Identifying status as offeror, issuer, or other person))**

**Options to purchase subordinate voting shares, no par value per share<br>(Title of Class of Securities)**

**CA22587M1068 for the subordinate voting shares<br>(CUSIP Number of Class of Securities)**

**John Schetz<br>Cresco Labs Inc.<br>600 West Fulton Street, Suite 800<br>Chicago, IL 60661<br>(312) 929-0993**

**(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)**

***Copy to:***

 **Heidi Steele<br>McDermott Will & Schulte LLP<br>444 West Lake Street, Suite 4000<br>Chicago, IL 60606<br>(312) 372-2000**

<br> ☐&nbsp;&nbsp;&nbsp;&nbsp;Check the box if filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☐&nbsp;&nbsp;&nbsp;&nbsp;third-party tender offer subject to Rule 14d-1.

☒&nbsp;&nbsp;&nbsp;&nbsp;issuer tender offer subject to Rule 13e-4.

☐&nbsp;&nbsp;&nbsp;&nbsp;going-private transaction subject to Rule 13e-3.

☐&nbsp;&nbsp;&nbsp;&nbsp;amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☒

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐&nbsp;&nbsp;&nbsp;&nbsp;Rule 13e-4(i) (Cross-Border Issuer Tender Offer)

☐&nbsp;&nbsp;&nbsp;&nbsp;Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

------

This Amendment to the Tender Offer Statement on Schedule TO (this "<u>Amendment</u>") amends and supplements the Tender Offer Statement on Schedule TO filed with the U.S. Securities and Exchange Commission on August 20, 2025 (together with its exhibits, the "<u>Schedule TO</u>"), by Cresco Labs Inc., a corporation organized under the laws of the Province of British Columbia (the "<u>Company</u>"), relating to the offer by the Company to certain optionholders to exchange (the "<u>Exchange Offer</u>") certain outstanding options to purchase the Company's subordinate voting shares for new restricted stock units (the "<u>New Awards</u>").

This Amendment is being filed in accordance with Rule 13e-4(c)(4) under the Securities Exchange Act of 1934, as amended, to report the final results of the Exchange Offer. Except as specifically set forth herein, this Amendment does not modify any of the information previously reported on the Schedule TO. You should read this Amendment together with the Schedule TO. All capitalized terms used herein have the same meanings as given in the Schedule TO.

**ITEM 4. &nbsp;&nbsp;&nbsp;&nbsp;Terms of the Transaction.**

Item 4(a) of the Schedule TO is hereby amended and supplemented by adding the following information:

(a)&nbsp;&nbsp;&nbsp;&nbsp; *Material Terms*.

Shareholder Approval of the Exchange Offer was obtained at the Company's annual general and special meeting held on September 16, 2025. The Exchange Offer expired at 11:59 p.m., Eastern Time, on Wednesday, September 17, 2025. Pursuant to the Exchange Offer, 14 Eligible Participants elected to exchange, and the Company accepted for cancellation, Eligible Options to purchase an aggregate of 8,865,902 subordinate voting shares, representing approximately 99% of the total subordinate voting shares underlying Eligible Options. On September 17, 2025, immediately following the expiration of the Exchange Offer, the Company granted 8,865,902 RSUs, pursuant and subject to the terms of the Exchange Offer and the 2018 Incentive Plan. The New Awards vest ratably over three years as described in the Exchange Offer.

**ITEM 12. &nbsp;&nbsp;&nbsp;&nbsp;Exhibits.**

Calculation of Filing Fee Tables

------

**SIGNATURE**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

---

| | | |
|:---|:---|:---|
| Cresco Labs Inc. | Cresco Labs Inc. | Cresco Labs Inc. |
| By: | /s/ Charles Bachtell | /s/ Charles Bachtell |
|  | Name: | Charles Bachtell |
|  | Title: | Chief Executive Officer |

---

Date: September 18, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit FILING FEE**

**CALCULATION OF FILING FEE TABLES**

**Table 1 – Transaction Valuation**

---

| | | | |
|:---|:---|:---|:---|
| (U.S. $) | **Transaction Valuation**<sup>(1)</sup> | **Fee Rate** | **Amount of Filing Fee**<sup>(2)</sup> |
| Fees to Be Paid | $— |  |  |
| Fees Previously Paid | $16737693.51 | 0.00015310 | $2562.54 |
| Total Transaction Valuation | $16737693.51 |  |  |
| Total Fees Due for Filing |  |  | $2562.54 |
| Total Fees Previously Paid |  |  | $2562.54 |
| Total Fee Offsets |  |  |  |
| Net Fee Due |  |  | $— |

---

(1) The fee of $2,562.54 was paid in connection with the filing of Schedule TO-I (File No. 005-92428) on August 20, 2025. This is the final amendment to the Schedule TO and is being filed to report the results of the offer.

(2) The amount of the filing fee, calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, and Fee Rate Advisory No. 1 for fiscal year 2025, equals $153.10 per million dollars of the transaction valuation.